09/28/2021 | Press release | Distributed by Public on 09/27/2021 17:36

EISAI INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB (BAN2401) FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL[...]

• For Print
• September 28, 2021

• Full text

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 View original format